TD Cowen Cuts Boston Scientific (NYSE:BSX) Price Target to $56.00

Boston Scientific (NYSE:BSX) had its price objective cut by TD Cowen from $61.00 to $56.00 in a research report sent to investors on Thursday,Benzinga reports. They currently have a buy rating on the medical equipment provider’s stock.

BSX has been the subject of several other reports. Stifel Nicolaus set a $60.00 target price on shares of Boston Scientific in a research report on Wednesday. Evercore set a $65.00 price target on shares of Boston Scientific in a report on Monday, July 6th. Citigroup lowered their price objective on shares of Boston Scientific from $70.00 to $61.00 and set a “buy” rating on the stock in a research report on Thursday. Canaccord Genuity Group dropped their price objective on shares of Boston Scientific from $70.00 to $66.00 and set a “buy” rating for the company in a report on Thursday. Finally, Raymond James Financial reiterated an “outperform” rating and issued a $57.00 target price on shares of Boston Scientific in a research report on Thursday. Twenty-four equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $71.62.

Boston Scientific Stock Performance

NYSE:BSX opened at $46.75 on Thursday. The business’s 50-day moving average price is $46.13 and its two-hundred day moving average price is $62.26. Boston Scientific has a twelve month low of $42.20 and a twelve month high of $109.50. The stock has a market cap of $69.48 billion, a P/E ratio of 18.93, a PEG ratio of 0.96 and a beta of 0.58. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.36% and a net margin of 17.50%.The firm had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter last year, the company posted $0.75 EPS. The company’s revenue for the quarter was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities analysts predict that Boston Scientific will post 3.3 EPS for the current fiscal year.

Boston Scientific announced that its Board of Directors has initiated a stock buyback program on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s board of directors believes its shares are undervalued.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director David C. Habiger acquired 2,250 shares of the business’s stock in a transaction dated Wednesday, May 20th. The stock was bought at an average price of $55.92 per share, with a total value of $125,820.00. Following the purchase, the director owned 13,878 shares of the company’s stock, valued at approximately $776,057.76. This trade represents a 19.35% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Edward J. Ludwig acquired 3,580 shares of the business’s stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average cost of $56.68 per share, with a total value of $202,914.40. Following the purchase, the director directly owned 25,359 shares in the company, valued at $1,437,348.12. This represents a 16.44% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired 9,800 shares of company stock worth $554,012 over the last ninety days. Insiders own 0.34% of the company’s stock.

Institutional Trading of Boston Scientific

Several hedge funds have recently added to or reduced their stakes in the business. Cary Street Partners Financial LLC boosted its position in Boston Scientific by 16.7% during the second quarter. Cary Street Partners Financial LLC now owns 25,092 shares of the medical equipment provider’s stock valued at $1,071,000 after buying an additional 3,597 shares during the period. Farther Finance Advisors LLC grew its stake in shares of Boston Scientific by 28.9% during the second quarter. Farther Finance Advisors LLC now owns 28,699 shares of the medical equipment provider’s stock valued at $1,227,000 after buying an additional 6,427 shares during the last quarter. Sequoia Financial Advisors LLC increased its holdings in shares of Boston Scientific by 2.3% in the second quarter. Sequoia Financial Advisors LLC now owns 49,355 shares of the medical equipment provider’s stock worth $2,106,000 after buying an additional 1,119 shares during the period. Simplify Asset Management Inc. increased its holdings in shares of Boston Scientific by 32.6% in the second quarter. Simplify Asset Management Inc. now owns 15,014 shares of the medical equipment provider’s stock worth $641,000 after buying an additional 3,690 shares during the period. Finally, Riversedge Advisors LLC bought a new stake in shares of Boston Scientific in the 2nd quarter valued at about $320,000. 89.07% of the stock is owned by institutional investors.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported second-quarter adjusted earnings of $0.86 per share and revenue of $5.44 billion, exceeding consensus estimates of $0.83 and $5.38 billion, respectively. Revenue increased 7.5% year over year, while management highlighted approximately 7% organic sales growth and a 15% increase in adjusted EPS. Boston Scientific Q2 earnings call highlights
• Positive Sentiment: Management’s multiyear restructuring plan is intended to improve efficiency and generate roughly $500 million in savings, supporting longer-term margins despite restructuring costs of up to $800 million. Reported workforce reductions are expected to affect operations in Ireland and Costa Rica. Boston Scientific restructuring cuts
• Positive Sentiment: Penumbra reported second-quarter revenue of $390.0 million, up 14.9% year over year, with thrombectomy revenue rising 12.5% and embolization and access revenue increasing 20.0%. The results provide supportive operating momentum for Boston Scientific’s pending acquisition of Penumbra, although PEN will not issue full-year guidance during the transaction. Penumbra second-quarter financial results
• Neutral Sentiment: Analyst sentiment remains broadly constructive but more cautious: UBS reaffirmed a Buy rating with a $74 target, while TD Cowen and Truist maintained Buy ratings despite lowering targets to $56 and $57. Argus reiterated a Hold rating, and BTIG reduced its expectations.
• Negative Sentiment: Boston Scientific lowered its full-year outlook because of headwinds affecting its electrophysiology and WATCHMAN portfolios. Analysts also cited a reset in expectations for these businesses, limiting the near-term upside from the earnings beat. Boston Scientific lowered full-year guidance
• Negative Sentiment: A recall involving the Rapid Refill Continuous Injection System adds a product and execution risk, while the restructuring will create near-term charges before expected savings are realized. Boston Scientific earnings, recall and restructuring

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.